MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy.
MiR-425 expression profiling in acute myeloid leukemia might guide the treatment choice between allogeneic transplantation and chemotherapy.
复制标题
急性髓系白血病中的 MiR™425 表达谱可能指导同种异体移植和化疗之间的治疗选择
DOI：
10.1186/s12967-018-1647-8
复制
发表时间：
2018-10-01
影响因子：
7.4
通讯作者：
Xu K
中科院分区：
文献类型：
--
作者：
Yang C;Shao T;Zhang H;Zhang N;Shi X;Liu X;Yao Y;Xu L;Zhu S;Cao J;Cheng H;Yan Z;Li Z;Niu M;Xu K
急性髓系白血病（AML）是一种高度异质性的疾病。microRNA是AML临床预后的重要生物标志物。本研究通过筛选TCGA数据集将miR-425鉴定为AML的预后因子。共162例AML患者入组研究，并分为化疗组和异基因造血干细胞移植（allo-HSCT）组。在化疗组中，与miR-425低表达患者相比，miR-425高表达患者的总生存期（OS）和无事件生存期（EFS）显著延长。在多变量分析中，与低miR-425表达的患者相比，高miR-425表达仍然独立预测更好的OS（HR = 0.502，P = 0.005）和EFS（HR = 0.432，P = 0.001）。然后，根据miR-425的中位表达水平将所有患者分为两组。值得注意的是，与低miR-425表达组中接受化疗的患者相比，接受allo-HSCT的患者具有显著更好的OS（HR = 0.302，P <0.0001）和EFS（HR = 0.379，P < 0.0001）。从机制上讲，高miR-425表达水平与显著参与调节细胞代谢的谱相关。在这些基因中，MAP 3 K5、SMAD 2和SMAD 5被预测为miR-425的靶基因。miR-425的表达可能有助于识别需要在化疗和allo-HSCT治疗方案之间选择最佳治疗策略的患者。miR-425低表达的患者可考虑早期allo-HSCT。
Acute myeloid leukemia (AML) is a highly heterogeneous disease. MicroRNAs function as important biomarkers in the clinical prognosis of AML. This study identified miR-425 as a prognostic factor in AML by screening the TCGA dataset. A total of 162 patients with AML were enrolled for the study and divided into chemotherapy and allogeneic hematopoietic stem cell transplantation (allo-HSCT) groups. In the chemotherapy group, patients with high miR-425 expression had significantly longer overall survival (OS) and event-free survival (EFS) compared with patients with low miR-425 expression. In multivariate analyses, high miR-425 expression remained independently predictive of a better OS (HR = 0.502, P = 0.005) and EFS (HR = 0.432, P = 0.001) compared with patients with low miR-425 expression. Then, all patients were divided into two groups based on the median expression levels of miR-425. Notably, the patients undergoing allo-HSCT had significantly better OS (HR = 0.302, P < 0.0001) and EFS (HR = 0.379, P < 0.0001) compared with patients treated with chemotherapy in the low-miR-425-expression group. Mechanistically, high miR-425 expression levels were associated with a profile significantly involved in regulating cellular metabolism. Among these genes, MAP3K5, SMAD2, and SMAD5 were predicted targets of miR-425. The expression of miR-425 may be useful in identifying patients in need of strategies to select the optimal therapy between chemotherapy and allo-HSCT treatment regimens. Patients with low miR-425 expression may consider early allo-HSCT.
登录
查看更多内容
影响因子：
4.5
作者：
Di Leva G;Piovan C;Gasparini P;Ngankeu A;Taccioli C;Briskin D;Cheung DG;Bolon B;Anderlucci L;Alder H;Nuovo G;Li M;Iorio MV;Galasso M;Santhanam R;Marcucci G;Perrotti D;Powell KA;Bratasz A;Garofalo M;Nephew KP;Croce CM
通讯作者：
Croce CM
影响因子：
16.6
作者：
Meng Z;Moroishi T;Mottier-Pavie V;Plouffe SW;Hansen CG;Hong AW;Park HW;Mo JS;Lu W;Lu S;Flores F;Yu FX;Halder G;Guan KL
通讯作者：
Guan KL
影响因子：
37.3
作者：
Ma J;Liu J;Wang Z;Gu X;Fan Y;Zhang W;Xu L;Zhang J;Cai D
通讯作者：
Cai D
影响因子：
5.3
作者：
Morris, Valerie A.;Cummings, Carrie L.;Oehler, Vivian G.
通讯作者：
Oehler, Vivian G.
影响因子：
45.3
作者：
Schwind, Sebastian;Maharry, Kati;Bloomfield, Clara D.
通讯作者：
Bloomfield, Clara D.